Company / PP&E per Share
Taysha Gene Therapies, Inc. PP&E per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E per Share
$0.03
FY2025
5-year range
$0.03 / $1.34
FY2021-FY2025
Trend
-17.9%
vs FY2024
Sector context
#132 of 191
Health Care
What the data says
At $0.03, Taysha Gene Therapies, Inc.'s pp&e per share ranks #132 of 191 in the Health Care sector. PP&E per Share has declined for 4 consecutive years, from $1.34 in FY2021 to $0.03 in FY2025.
Based on SEC 10-K filings.
0.03 in FY2025 with a 5-year CAGR of +15.1%.
Declined from $0.17 to $0.03 over the past 2 years.
Health Care sector context is included.
PP&E per Share over time
Growth rates
- 3-Year CAGR
- -56.1%
- 5-Year CAGR
- +15.1%
- 10-Year CAGR
- -
Sector benchmark
#132 of 191 in Health CareTop 69% of 191This company $0.03 Sector average $22.34
▼
-99.9% below sector average
Key checks
Key Insights
- Taysha Gene Therapies, Inc.'s pp&e per share has declined for 4 consecutive years.
- In FY2025, pp&e per share decreased 17.9% year-over-year.
- Ranks #132 out of 191 companies in the Health Care sector.
- Peak pp&e per share was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.03 | -17.9% |
| FY2024 | $0.04 | -76.6% |
| FY2023 | $0.17 | -56.0% |
| FY2022 | $0.39 | -71.1% |
| FY2021 | $1.34 | +8174.0% |
| FY2020 | $0.02 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026